ESRACAIN INJECTION 1%

Country: Israel

Bahasa: Inggeris

Sumber: Ministry of Health

Beli sekarang

Ciri produk Ciri produk (SPC)
22-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
12-05-2022

Bahan aktif:

LIDOCAINE HYDROCHLORIDE

Boleh didapati daripada:

RAFA LABORATORIES LTD

Kod ATC:

N01BB02

Borang farmaseutikal:

SOLUTION FOR INJECTION

Komposisi:

LIDOCAINE HYDROCHLORIDE 10 MG/ML

Laluan pentadbiran:

I.M, EPIDURAL, S.C, INTRADERMAL, SUBMUCOSAL, SPINAL, PERINEURAL, I.V REGIONAL ANAESTHESIA

Jenis preskripsi:

Required

Dikeluarkan oleh:

RAFA LABORATORIES LTD, JERUSALEM

Kumpulan terapeutik:

LIDOCAINE

Kawasan terapeutik:

LIDOCAINE

Tanda-tanda terapeutik:

Local and regional anesthesia.

Tarikh kebenaran:

2021-11-30

Ciri produk

                                Esracaine Injection 1%
-DL-SPC-December 2023-02
Summary of Product Characteristics
1
NAME OF THE MEDICINAL PRODUCT
Esracain Injection 1%
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml of Esracain Injection 1% contains 10 mg lidocaine
hydrochloride (monohydrate).
_Excipients with known effect:_
Sodium (as sodium chloride and sodium hydroxide): about 1.2 mmol (28
mg) sodium per 10 ml solution.
See also section 4.4.
For a full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Solution for injection
Clear, colourless aqueous solution in clear ampoules.
4
CLINICAL PARTICULARS
4.1
Therapeutic Indications
Local and regional anaesthesia.
4.2
Posology and method of administration
Posology
_Local and regional anaesthesia_
As a matter of principle the smallest possible dose that produces
adequate anaesthesia should be
administered. The dosage should be adjusted individually according to
the particulars of each case.
Adults:
When injected into tissues with marked systemic absorption, without
combination with a vasoconstrictor, a
single dose of lidocaine hydrochloride monohydrate should not exceed
4.5 mg/kg body weight (BW) (or 300
mg). If combined with a vasoconstrictor, 7 mg/kg BW (or 500 mg) of
lidocaine hydrochloride monohydrate per
single dose should not be exceeded.
For the clinical uses listed below, recommendations for single doses
and strengths of the injection solution to
be administered to adults with average body weight (70 kg) are as
follows:
Type of anaesthesia
Concentration [%]
Usual volume [ml]
Maximum dose [mg]
Infiltration
0.5-1
300
500 (with epinephrine)
Major nerve blocks
1-2
30-50
500 (with epinephrine)
Minor nerve blocks
1
5-20
200
Epidural
1-2
15-30*
500 (with epinephrine)
Spinal
1.5 or 5 in 7.5% glucose
1-2
100
Intravenous regional anaesthesia (IVRA)
-upper limb
-lower limb
0.5
0.25
40
50-100
*1.5 ml per segment in average
For prolongation of anaesthesia lidocaine may be combined with a
vasoconstrictor, e.g. epinephrine. Addition
of epinephrine at a concentration of 1:100 000 to 1:200 00
                                
                                Baca dokumen lengkap
                                
                            

Cari amaran yang berkaitan dengan produk ini